Muscle-invasive bladder cancer in a patient with hearing loss and borderline renal function
A 68-year-old man presents with painless gross haematuria. He has hypertension, a 40 pack-year smoking history, and bilateral sensorineural hearing loss requiring hearing aids. Examination is unremarkable. CT urography shows a 4.5 cm left lateral wall bladder mass without hydronephrosis and no enlarged lymph nodes or distant lesions. Complete transurethral resection achieves visibly complete resection; histology shows high-grade urothelial carcinoma invading the muscularis propria (pT2), with no lymphovascular invasion and no variant histology. Creatinine is 1.5 mg/dL, eGFR 47 mL/min/1.73 m², and ECOG performance status is 0. The patient is active, works full-time, and is strongly motivated to preserve his lifestyle but is concerned about "losing his bladder". He asks about chemotherapy, the chance of cure, and whether a neobladder is possible.
1. Is this patient cisplatin-eligible, and what neoadjuvant strategy would you recommend? Justify your reasoning.
Read the worked answer
Standard cisplatin eligibility requires ECOG 0–1, creatinine clearance or eGFR ≥60 mL/min, no grade ≥2 peripheral neuropathy, no clinically significant hearing loss, and no NYHA III–IV heart failure. This patient fails two criteria: eGFR 47 and pre-existing hearing loss requiring hearing aids. Split-dose cisplatin is sometimes used down to eGFR 40–50, but ototoxicity remains a real concern and audiology would be required; I would not offer it as standard here.
Options are therefore:
- Neoadjuvant gemcitabine–carboplatin: commonly used but supported by weaker pathological downstaging data than cisplatin-based regimens; reasonable if the patient prioritises systemic therapy before surgery.
- Proceed to radical cystectomy with pelvic lymphadenectomy and give adjuvant nivolumab if high-risk features (pT3–4 or node-positive) are found, based on CheckMate 274.
- Clinical trial or bladder-preserving trimodality therapy if he declines cystectomy, though chemoradiation is incompatible with a neobladder.
I would explain that neoadjuvant cisplatin-based chemotherapy has the strongest survival evidence, but the hearing loss and renal function make it unsafe. The decision should be shared, with cystectomy not delayed unnecessarily.
2. If he undergoes radical cystectomy, what urinary diversion do you propose and which preoperative factors determine this?
Read the worked answer
An orthotopic neobladder is feasible in principle because the tumour is on the lateral wall, not at the bladder neck or trigone, and he is motivated. However, eGFR 47 is borderline: neobladder function depends on good renal reserve, and renal function often declines further after cystectomy. I would assess the urethral margin by frozen section, exclude urethral stricture, and confirm manual dexterity and willingness to perform clean intermittent catheterisation. I would counsel him that 10–30% of patients require catheterisation, nocturnal incontinence is common, and a neobladder is not a guarantee of normal voiding.
If any of these are unfavourable, an ileal conduit is safer. Body habitus, prior abdominal surgery, stoma site marking, and patient preference all matter. The key judgement is not to promise a neobladder before confirming a negative urethral margin and realistic renal reserve.
3. He asks whether chemotherapy and radiotherapy can replace cystectomy. How do you counsel him?
Read the worked answer
Trimodality therapy-complete transurethral resection followed by concurrent chemoradiation-is a legitimate alternative in selected patients, with 5-year overall survival broadly comparable to cystectomy in non-randomised series. It requires a visibly complete resection, no hydronephrosis, good bladder function, and fitness for chemotherapy. This patient has a complete resection and no hydronephrosis, so he is a reasonable candidate.
I would explain the trade-offs: trimodality preserves the native bladder in about 70–80% of patients, but requires close surveillance, causes irritative urinary symptoms, and about 20–30% eventually need salvage cystectomy. It is not compatible with a neobladder. His hearing loss does not preclude radiotherapy. If he opts for bladder preservation, he must accept the possibility of salvage surgery and the need for lifelong cystoscopic follow-up. I would not present radiotherapy as equivalent to cystectomy in all respects.